Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer

Figure 3

Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS). (A and B) PFS and OS curves according to the positivity or the negativity of MUC1 mRNA in blood of NSCLC patients before (B0) and 4 weeks after the start of treatment (B4w). (C and D) PFS and OS curves according to the positivity or the negativity of VEGF mRNA in blood of NSCLC patients at B0 and B4w time points.

Back to article page